News
03-23-2010, 09:20 AM
Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. announced that they have temporarily suspended the clinical program for Stimuvax® (BLP25 liposome vaccine) in all recruiting studies worldwide as a result of a suspected unexpected serious adverse reaction (SUSAR). This decision was taken in alignment with the U.S...
More... (http://mnt.to/f/3zkd)
More... (http://mnt.to/f/3zkd)